Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab

NCT01734382 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01734382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01734382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
June 10, 2013
Completion date
October 9, 2019
Enrollment
35 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis